Odyssey Therapeutics
Presence
Acquisition, funding and merger involving Odyssey Therapeutics.
- Odyssey Therapeutics has just announced a $101 Million fundraising (posted on December 5 2023).
- Odyssey Therapeutics has just announced a $168 Million fundraising (posted on October 18 2022).
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Odyssey Therapeutics
- Gary Glick, President and Chief Executive Officer
- Jeff Hermes, Executive Vice President of Enabling Sciences
- Will Smiley, Head of Human Resources
Popular executive movements at Odyssey Therapeutics
- Julie Clauss has joined the company as Chief Operating Officer (posted on April 3 2024).
- Christopher Butler has joined the company as Senior Vice President and Head of Chemistry (posted on April 3 2024).
- Jeremy Sokolove has joined the company as Chief Medical Officer (posted on October 5 2023).
Create your alert
to follow the executive moves at Odyssey Therapeutics.
Biotechnology
Odyssey Therapeutics has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Odyssey Therapeutics
Social media about Odyssey Therapeutics
- Odyssey Therapeutics on Wikipedia, Google News & Yahoo Finance
- Odyssey Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Gary Glick 
Call Odyssey Therapeutics at +1 973...
